| Literature DB >> 34178641 |
Gumuyang Zhang1, Zhe Wu2, Lili Xu1, Xiaoxiao Zhang1, Daming Zhang1, Li Mao3, Xiuli Li3, Yu Xiao4, Jun Guo2, Zhigang Ji5, Hao Sun1, Zhengyu Jin1.
Abstract
BACKGROUND: Clinical treatment decision making of bladder cancer (BCa) relies on the absence or presence of muscle invasion and tumor staging. Deep learning (DL) is a novel technique in image analysis, but its potential for evaluating the muscular invasiveness of bladder cancer remains unclear. The purpose of this study was to develop and validate a DL model based on computed tomography (CT) images for prediction of muscle-invasive status of BCa.Entities:
Keywords: artificial intelligence; bladder cancer; computed tomography; computed-assisted; deep learning; diagnosis
Year: 2021 PMID: 34178641 PMCID: PMC8226179 DOI: 10.3389/fonc.2021.654685
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1The study flow and the recruitment pathway. BC, bladder cancer; TURBT, transurethral resection of bladder tumor; CTU, computed tomography urography.
Figure 2Workflow of the deep learning model for the prediction of muscle invasiveness status in bladder cancer patients. (A) Collection of the CT images of MIBC and NMIBC. (B) Semiautomatic segmentation of the tumor region. (C) The masked tumor region and the original tumor region were stacked vertically to form the input volume, and the cropped 2-channel input was constructed. (D) The structure of our deep-learning model. The model was constructed on the basis of Filter-guided Pyramid Network (FGP-Net), a novel 3D convolutional network structure that is designed to capture the global feature and the local features simultaneously. (E) Internal and external validation of our model. CT, computed tomography; FC, fully connected layer.
Clinical characteristics of patients with bladder cancer.
| Characteristics | Training cohort*(n=293) | Internal validation cohort (n=73) | External validation cohort (n=75) | p-value |
|---|---|---|---|---|
| Age | 0.038 | |||
| Median (IQR) | 65 (56,72) | 68 (61,74) | 65 (59,77) | |
| Gender | 0.166 | |||
| Female | 75 (25.6) | 13 (17.8) | 13 (17.3) | |
| Male | 218 (74.4) | 60 (82.2) | 62 (82.7) | |
| CT-reported number of lesions | 0.016 | |||
| Unifocal | 229 (78.2) | 66 (90.4) | 54 (72.0) | |
| Multifocal | 64 (21.8) | 7(9.6) | 21 (28.0) | |
| CT-reported largest lesion diameter (cm) | 0.063 | |||
| Mean ± SD | 2.71 ± 1.67 | 2.33 ± 1.62 | 2.78 ± 1.70 | |
| ≤3 | 188 (64.2) | 57 (78.1) | 52 (69.3) | |
| >3 | 105 (35.8) | 16 (21.9) | 23 (30.7) | |
| CT attenuation of the largest lesion (HU) | 0.030 | |||
| Mean ± SD | 67.1 ± 14.0 | 56.3 ± 20.9 | 70.5 ± 13.0 | |
| Pathologic T stage | 0.010 | |||
| ≤T1 | 217 (74.1) | 58 (79.5) | 44 (58.7) | |
| ≥T2 | 76 (25.9) | 15 (20.5) | 31 (41.3) |
*The training cohort (n=293) is the combination of the development (n=183) and tuning (n=110) cohorts. IQR, interquartile; SD, standard deviation.
Figure 3Performance of the deep learning model for the differentiation of MIBC and NMIBC. (A) Receiver operator characteristic curves of the model in four different cohorts. (B) Comparison of the performance between the model and two radiologists. (C) Calibration curves of the model in internal and external validation cohorts. The calibration curve showed that the predicted probabilities generally agreed with the observed probabilities. The predictive performance of the model in the external validation cohort exhibited a closer fit to the perfect calibration. (D, E) showed decision curve analyses (DCA) in the internal and external validation cohorts respectively. DCA compared the net benefit of the deep learning model versus treat all or treat none are shown. The net benefit was plotted versus the threshold probability. The net benefits of the deep learning model (blue line) were superior to the benefits of treating all or treating none.
Performance of the model in development, tuning and validation cohorts.
| AUC (95%CI) | Accuracy (95%CI) | Sensitivity (95%CI) | Specificity (95%CI) | |
|---|---|---|---|---|
| Development cohort | 0.936 | 0.836 | 0.872 | 0.824 |
| Tuning cohort | 0.891 | 0.800 | 0.828 | 0.790 |
| Internal validation cohort (n=73) | 0.861 | 0.795 | 0.733 | 0.810 |
| External validation cohort (n=75) | 0.791 | 0.747 | 0.710 | 0.773 |
AUC, area under the receiver operating characteristics curve; CI, confidence interval.
Performance of two radiologists and the deep learning model on validation cohorts.
| Validation cohort | Reader | Accuracy(95%CI) | Sensitivity(95%CI) | Specificity(95%CI) |
|---|---|---|---|---|
| Internal | Reader 1 | 0.685 | 0.933 | 0.621 |
| Reader 2 | 0.585 | 0.800 | 0.517 | |
| Model | 0.795 | 0.733 | 0.810 | |
| Reader 1 | 0.747 | 0.774 | 0.727 | |
| External | Reader 2 | 0.573 | 0.839 | 0.386 |
| Model | 0.747 | 0.710 | 0.773 |
AUC, area under the receiver operating characteristics curve; CI, confidence interval.
Figure 4Illustrations of the performance of the deep learning model. (A) Violin plots of predictive scores in the development, tuning, internal validation and external validation cohorts. (B, C) showed waterfall plots of the distribution of predictive scores and muscle invasive status of each patient in the internal and external validation cohorts respectively.
Figure 5Examples of feature maps from validation cohorts and visualization of the effectiveness of the learned features. (A) Two cases from MIBC and two cases from NMIBC are shown. The active regions were mainly overlaid on the areas with visual characteristics that were helpful for discriminating between MIBC and NMIBC, including the internal region of the tumor, corresponding bladder wall, and the surrounding outside pelvic fat. (B) Colored points represent the NIMBC (blue) and MIBC (orange). Effective features were learned by the model, and the two categories of nodules were well clustered. The eight examples show images corresponding to circled points. Nodules in sets a and c were highly discriminated by the model, whereas nodules in sets b and d were less discriminated because they shared similar features with the opposite tumor.